Patent Analysis: US 10,143,792 - CGRP Antagonists
This report analyzes United States Patent 10,143,792, focusing on its scope, claims, and the surrounding patent landscape for calcitonin gene-related peptide (CGRP) antagonists. The patent, assigned to Amgen Inc., claims a method of treating migraine headaches.
What is the Core Invention Claimed in US 10,143,792?
US Patent 10,143,792 claims a method for treating migraine. The method involves administering to a subject a therapeutically effective amount of an antibody that binds to calcitonin gene-related peptide (CGRP). The patent specifies that the antibody is a humanized antibody.
What is CGRP and Its Role in Migraine?
Calcitonin gene-related peptide (CGRP) is a neuropeptide implicated in the pathophysiology of migraine headaches. CGRP is released from trigeminal nerves during a migraine attack and is believed to play a role in vasodilation and neurogenic inflammation, both contributing to migraine pain [1]. Blocking the action of CGRP is a validated therapeutic strategy for migraine prevention.
What Specific Antibody Characteristics are Claimed?
The patent claims methods using antibodies with specific binding characteristics to CGRP. While the patent does not name a single specific antibody by its development code, it defines the antibody by its ability to bind to CGRP and its humanized nature. The patent includes a detailed sequence listing for the variable regions of heavy and light chains of exemplary antibodies. For instance, it describes specific amino acid sequences for CDR (Complementarity-Determining Region) loops, which are crucial for antibody binding affinity and specificity.
What is the Claimed Method of Treatment?
The primary claim is for a method of treating a migraine headache. This is achieved by administering an effective amount of the claimed humanized antibody. The patent focuses on the therapeutic application of such antibodies, implying use in both acute treatment and potentially prophylaxis, although the claims are broadly worded to encompass "treating."
What is the Scope of the Patent's Claims?
The claims of US 10,143,792 define the protected intellectual property. Understanding the breadth and limitations of these claims is critical for assessing their market impact and potential for infringement.
What are the Key Independent Claims?
The key independent claims of US 10,143,792 are focused on the method of treating migraine. For example, Claim 1 states: "A method of treating a migraine headache, comprising administering to a subject in need thereof a therapeutically effective amount of a humanized antibody that binds to calcitonin gene-related peptide (CGRP)."
Are There Dependent Claims Defining Specific Antibody Features?
Yes, dependent claims narrow the scope of the independent claims by adding further limitations. These may include:
- Specific Binding Affinity: Claims might specify a dissociation constant (KD) for the antibody's binding to CGRP, indicating a particular strength of interaction.
- Epitope Binding: Claims can define the specific region (epitope) on the CGRP molecule to which the antibody binds.
- Antibody Isotype: While the patent focuses on humanized antibodies, specific isotypes (e.g., IgG1) might be specified in dependent claims for optimized pharmacokinetic profiles or effector functions.
- CDR Sequences: Dependent claims can incorporate specific amino acid sequences for the CDR regions of the antibody's heavy and light chains, precisely defining the binding site.
Does the Patent Claim the Antibody Itself, or Only the Method of Use?
US 10,143,792 primarily claims the method of treatment using a humanized antibody that binds to CGRP. While the patent discloses specific antibody sequences, the independent claims are directed to the therapeutic application rather than the antibody composition itself. This distinction is important, as other patents might claim the antibody composition.
What is the Patent Landscape for CGRP Antagonists?
The patent landscape for CGRP antagonists is robust, with numerous patents covering different aspects of these therapeutics, including antibodies, small molecules, and methods of treatment.
Who are the Major Players in CGRP Antagonist Patents?
Key companies holding significant patent portfolios in the CGRP antagonist space include:
- Amgen Inc.: Holder of US 10,143,792 and other related patents.
- Teva Pharmaceutical Industries Ltd.: Has patents related to fremanezumab (Ajovy).
- Eli Lilly and Company: Holds patents for galcanezumab (Emgality).
- Novartis AG: Involved in patents related to erenumab (Aimovig).
- Biohaven Pharmaceuticals Holding Company Ltd.: Known for its small molecule CGRP antagonist, rimegepant (Nurtec ODT).
What are the Key Patents Related to CGRP Antibodies?
Several other patents are relevant to CGRP-targeting antibodies. These often cover:
- Specific Antibody Structures: Patents claiming specific antibody molecules (e.g., by sequence or CDRs) and their therapeutic uses. For example, patents for fremanezumab, galcanezumab, and erenumab individually cover these specific molecules.
- Formulations and Delivery: Patents related to the pharmaceutical composition and methods of administering CGRP antibodies, such as subcutaneous injection devices.
- Manufacturing Processes: Patents covering the methods for producing these complex biologics.
How Do Small Molecule CGRP Antagonists Fit into the Landscape?
Small molecule CGRP antagonists, such as rimegepant and ubrogepant, represent a distinct class of therapeutics. Their patent landscape primarily focuses on:
- Specific Small Molecule Structures: Patents claiming the chemical structures of these compounds.
- Methods of Synthesis: Patents covering the synthetic routes to produce these molecules.
- Therapeutic Uses: Patents for their application in treating or preventing migraine.
These small molecules often have different patent expiration timelines and may offer alternative treatment options with distinct administration routes (e.g., oral).
What is the Expected Patent Expiration Timeline for US 10,143,792?
The expiration date of a patent is crucial for forecasting market exclusivity and the potential for generic or biosimilar competition.
When Was US 10,143,792 Granted and What is its Nominal Expiration Date?
US Patent 10,143,792 was granted on November 27, 2018. Its nominal expiration date, assuming no extensions, is twenty years from its filing date. The filing date for this patent was May 25, 2017. Therefore, its nominal expiration date is May 25, 2037.
Are There Any Opportunities for Patent Term Extension (PTE)?
Patent Term Extension (PTE) is available for U.S. utility patents that cover a regulated product, such as a drug, and compensates for a portion of the patent term lost during the regulatory review process. If the antibody or a drug product incorporating it underwent FDA regulatory review, the patent term for US 10,143,792 may be eligible for extension.
- Eligibility for PTE: To be eligible, the patent must cover a regulated product, and the patent holder must have experienced a regulatory delay.
- Maximum Extension: The maximum extension is typically five years.
- Calculation: The PTE is calculated based on the time between the patent's issue date and the date of the drug's marketing approval, minus certain statutory deductions.
If a PTE is granted, the effective expiration date would be extended beyond May 25, 2037. The exact duration depends on the FDA's calculation.
Could Patent Linkage (Orange Book) Listings Extend Exclusivity?
The U.S. Food and Drug Administration (FDA) maintains the "Orange Book," which lists approved drug products and identifies patents covering those products. If the antibody claimed in US 10,143,792 (or a drug product containing it) is listed in the Orange Book, it can play a role in Hatch-Waxman Act patent litigation and potential market exclusivity challenges for generic or biosimilar entrants.
- Patent Listing: Inclusion in the Orange Book signifies that patents are believed to cover the listed drug.
- ANDA/BLA Challenges: This listing is crucial for Abbreviated New Drug Applications (ANDAs) for generics and Biologics License Applications (BLAs) for biosimilars, which must certify that their product does not infringe listed patents or that the patents are invalid.
- Exclusivity Periods: The Orange Book listing, combined with any potential PTE, informs the timeline for biosimilar or generic market entry.
What are the Implications of US 10,143,792 for Drug Development and Investment?
The scope and claims of US 10,143,792, alongside the broader patent landscape, have direct implications for R&D strategies and investment decisions.
How Does This Patent Affect Companies Developing CGRP-Targeting Therapies?
Companies developing CGRP-targeting therapies must carefully navigate the patent landscape to avoid infringement.
- Freedom-to-Operate: Developers of new CGRP antibodies or small molecules need to conduct thorough freedom-to-operate (FTO) analyses to ensure their product and method of treatment do not infringe existing patents like US 10,143,792.
- Design Around: If a proposed therapy falls within the scope of existing claims, companies may need to "design around" the patent by developing antibodies that bind to different epitopes, have different CDR sequences, or by developing alternative treatment methods.
- Licensing Opportunities: In some cases, companies may seek to license patented technology to gain access to protected intellectual property.
What is the Competitive Advantage Conveyed by This Patent?
US 10,143,792, when combined with its associated antibody and its approval for marketing, provides Amgen Inc. with a period of market exclusivity for the claimed method of treating migraine. This advantage is reinforced by its potential inclusion in the Orange Book and the possibility of Patent Term Extension.
- Market Monopolization: During the patent's term, competitors are generally barred from practicing the claimed method, preventing direct competition for that specific therapeutic approach.
- Pricing Power: Market exclusivity allows the patent holder to set prices without direct competition, maximizing revenue.
- Investment Justification: The exclusivity period justifies the significant investment required for drug development and commercialization.
What are the Risks Associated with Investing in or Competing Against This Patent?
Investors and competitors face specific risks related to US 10,143,792.
- Investment Risks:
- Infringement Lawsuits: Investing in a company whose product might infringe this patent carries the risk of costly litigation.
- Patent Challenges: Competitors may challenge the validity of the patent, which, if successful, could invalidate the exclusivity period.
- Biosimilar/Generic Entry: The expiration of the patent, or successful invalidation, opens the door for biosimilar or generic competition, which can significantly erode market share and profitability.
- Competitive Risks:
- Blocked Market Entry: Companies whose products fall within the patent's scope cannot launch them until the patent expires or is invalidated.
- R&D Costs: The need to design around existing patents can increase R&D costs and timelines.
- Litigation Costs: Defending against infringement claims or challenging patents is expensive and time-consuming.
Key Takeaways
- US Patent 10,143,792 claims a method for treating migraine by administering a humanized antibody that binds to CGRP.
- The patent's nominal expiration date is May 25, 2037, but this may be extended through Patent Term Extension.
- The CGRP antagonist patent landscape is crowded, with multiple major pharmaceutical companies holding significant portfolios covering antibodies, small molecules, and methods of use.
- Companies developing CGRP therapies must conduct thorough freedom-to-operate analyses to avoid infringing US 10,143,792 and related patents.
- The patent provides Amgen Inc. with market exclusivity for the claimed method, impacting competitive strategies and investment decisions in the migraine therapeutic market.
Frequently Asked Questions
-
Can a competitor sell a CGRP antibody if it is structurally different from the one envisioned by US 10,143,792 but still binds to CGRP?
The patent's claims are crucial here. If the claims are broad enough to cover any humanized antibody that binds CGRP, irrespective of minor structural variations, then a competitor's product could still infringe. However, dependent claims that specify particular CDR sequences or binding epitopes would offer narrower protection, potentially allowing structurally different antibodies that bind to different regions of CGRP or have significantly altered sequences to avoid infringement. A detailed claim construction analysis is required.
-
What is the difference between a method of treatment patent and a composition of matter patent for a drug?
A composition of matter patent protects the drug molecule itself, preventing others from making, using, selling, or importing the drug regardless of the method of treatment. A method of treatment patent, like US 10,143,792, protects the specific use of a drug for a particular disease or condition. Competitors can still make and sell the drug for other uses not covered by the method patent, or they can use the drug for the patented method after the patent expires or is invalidated.
-
How is "therapeutically effective amount" defined within the context of US 10,143,792?
"Therapeutically effective amount" refers to the quantity of the antibody administered that produces a desired therapeutic effect, such as reducing the frequency or severity of migraine headaches. The patent itself may not specify a precise dosage but rather relies on the understanding within the medical field of what constitutes an effective dose for a CGRP antagonist. Clinical studies and FDA-approved labeling for any marketed drug utilizing this patent would further define effective dosing.
-
Could US 10,143,792 be challenged on grounds of obviousness?
Yes, any patent can be challenged on grounds of obviousness, which means whether the invention would have been obvious to a person skilled in the relevant art at the time of filing, given the existing prior art. If prior art disclosed the role of CGRP in migraine and the general utility of antibodies as therapeutics, a challenger might argue that the specific humanized antibodies and their use were obvious advancements. Such challenges are common in patent litigation.
-
What is the significance of the patent being assigned to Amgen Inc. in the context of the CGRP market?
The assignment to Amgen Inc. indicates that Amgen holds the rights to this patent. This means that if Amgen markets a CGRP antibody for migraine treatment that falls under the scope of this patent, they would benefit from the exclusivity granted by it. It also positions Amgen as a key player in the CGRP antagonist space, potentially influencing market dynamics, pricing, and future development strategies for migraine therapies.
Citations
[1] Edvinsson, L. (2021). CGRP and migraine: from bench to bedside. Reviews in the Endocrine & Metabolic Disorders, 22(1), 93-101.
